Free Shipping on Orders Over $75! Ends January 31st.

Your Trusted Brand for Over 35 Years

Daily News

Data on Anxiety Disorders Reported by Researchers at Shenyang Pharmaceutical University (Silibinin ameliorates anxiety/depression-like behaviors in...

Obesity, Fitness & Wellness Week

10-20-17

Data on Anxiety Disorders Reported by Researchers at Shenyang Pharmaceutical University (Silibinin ameliorates anxiety/depression-like behaviors in amyloid beta-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in ...)

By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Mental Health Diseases and Conditions - Anxiety Disorders. According to news reporting originating in Shenyang, People's Republic of China, by NewsRx journalists, research stated, "Depression is one of the most frequent psychiatric disorders of Alzheimer's disease (AD). Depression and muddy are associated with increased risk of developing AD."

The news reporters obtained a quote from the research from Shenyang Pharmaceutical University, "Silibinin, a flavonoid derived from milk thistle (Silybum marianum), has been used as a hepato-protectant in the clinical treatment of liver diseases. In this study, the effect of silibinin on A beta-induced anxiety/depression-like behaviors in rats was investigated. Silibinin significantly attenuated anxiety/depression-like behaviors caused by A beta 1-42-treatment as shown in tail suspension test (TST), elevated plus maze (EPM) and forced swimming tests (FST). Moreover, silibinin was able to attenuate the neuronal damage in the hippocampus of A beta 1-42-injected rats. Silibinin-treatment up-regulated the function through BDNF/TrkB pathway and attenuated autophagy in the hippocampus."

According to the news reporters, the research concluded: "Our study provides a new insight into the protective effects of silibinin in the treatment of anxiety/depression."

For more information on this research see: Silibinin ameliorates anxiety/depression-like behaviors in amyloid beta-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus. Physiology & Behavior, 2017;179():487-493. Physiology & Behavior can be contacted at: Pergamon-Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. (Elsevier - www.elsevier.com; Physiology & Behavior - www.journals.elsevier.com/physiology-and-behavior/)

Our news correspondents report that additional information may be obtained by contacting T. Ikejima, Shenyang Pharmaceutical University, China Japan Res Inst Med & Pharmaceut Sci, Shenyang 110016, People's Republic of China. Additional authors for this research include B. Liu, L.Y. Cui, B.A. Zhou, W.W. Liu, F.X. Xu, T. Hayashi, S. Hattori, Y. Ushiki-Kaku, S. Tashiro and X.Y. Song (see also Mental Health Diseases and Conditions - Anxiety Disorders).

Keywords for this news article include: Shenyang, People's Republic of China, Asia, Peptides and Proteins, Risk and Prevention, Mental Health Diseases and Conditions, Anxiety Disorders, Amyloid, Shenyang Pharmaceutical University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.